In Segment A, individuals will acquire various doses and schedules of oral ABBV-744 pill to recognize Harmless dosing regimen. Added contributors will likely be enrolled for the identified monotherapy dosign regimen. In Segment B, individuals will acquire oral ruxolitinib and ABBV-744 will likely be supplied as "add-on" therapy. In Segment https://abbv-744-brd4-inhibition37912.tusblogos.com/32002095/the-fact-about-abbv-744-in-combination-with-immunotherapy-that-no-one-is-suggesting